Academic Journal
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
| العنوان: | Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52 |
|---|---|
| المؤلفون: | Steven R. Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadło-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee Rho |
| المصدر: | Journal of Dermatological Treatment, Vol 35, Iss 1 (2024) |
| بيانات النشر: | Taylor & Francis Group, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Dermatology |
| مصطلحات موضوعية: | Psoriasis, ustekinumab, biologics, biosimilar, randomized clinical trial, Dermatology, RL1-803 |
| الوصف: | Introduction SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.Methods Subjects were randomized to receive 45 mg of SB17 or UST subcutaneously up to Week 40. At Week 28, subjects from the UST treatment group were re-randomized to either switch to SB17 or continue UST. Efficacy, safety, and immunogenicity were assessed up to Week 52.Results Among baseline randomized 503 subjects, 481 subjects were re-randomized at Week 28; continuing SB17 (SB17 + SB17, n = 237), switching from UST to SB17 (UST+SB17, n = 122) or continuing UST (UST+UST, n = 122). The percent change from baseline in Psoriasis Area and Severity Index (PASI) was comparable between treatment groups up to Week 52 (SB17 + SB17: 95.8%, UST+SB17: 95.6%, UST+UST: 94.5% at Week 52). Other efficacy endpoints were also comparable. The incidence of treatment-emergent adverse events (SB17 + SB17: 16.5%, UST+SB17: 13.9%, UST+UST: 23.8%) and the overall incidence of anti-drug antibodies occurring after transition were comparable between treatment groups (SB17 + SB17: 5.6%, UST+SB17: 5.1%, and UST+UST: 6.7%).Conclusion SB17 demonstrated clinical biosimilarity to UST after switching from UST, and maintained long-term comparable efficacy and safety with UST up to Week 52. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 09546634 1471-1753 0954-6634 |
| Relation: | https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753 |
| DOI: | 10.1080/09546634.2024.2436607 |
| URL الوصول: | https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041 |
| رقم الانضمام: | edsdoj.6c23eae0b2e24e7484f961e0f4edf041 |
| قاعدة البيانات: | Directory of Open Access Journals |
| ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.6c23eae0b2e24e7484f961e0f4edf041 1055 3 Academic Journal academicJournal 1055.36608886719 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.6c23eae0b2e24e7484f961e0f4edf041&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Steven+R%2E+Feldman%22">Steven R. Feldman</searchLink><br /><searchLink fieldCode="AR" term="%22Joanna+Narbutt%22">Joanna Narbutt</searchLink><br /><searchLink fieldCode="AR" term="%22Giampiero+Girolomoni%22">Giampiero Girolomoni</searchLink><br /><searchLink fieldCode="AR" term="%22Jan+Brzezicki%22">Jan Brzezicki</searchLink><br /><searchLink fieldCode="AR" term="%22Nataliya+Reznichenko%22">Nataliya Reznichenko</searchLink><br /><searchLink fieldCode="AR" term="%22Maria+Agnieszka+Zegadło-Mylik%22">Maria Agnieszka Zegadło-Mylik</searchLink><br /><searchLink fieldCode="AR" term="%22Grazyna+Pulka%22">Grazyna Pulka</searchLink><br /><searchLink fieldCode="AR" term="%22Magdalena+Dmowska-Stecewicz%22">Magdalena Dmowska-Stecewicz</searchLink><br /><searchLink fieldCode="AR" term="%22Elżbieta+Kłujszo%22">Elżbieta Kłujszo</searchLink><br /><searchLink fieldCode="AR" term="%22Dmytro+Rekalov%22">Dmytro Rekalov</searchLink><br /><searchLink fieldCode="AR" term="%22Lidia+Rajzer%22">Lidia Rajzer</searchLink><br /><searchLink fieldCode="AR" term="%22Jiyoon+Lee%22">Jiyoon Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Minkyung+Lee%22">Minkyung Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Young+Hee+Rho%22">Young Hee Rho</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Journal of Dermatological Treatment, Vol 35, Iss 1 (2024) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Taylor & Francis Group, 2024. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2024 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Dermatology ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Psoriasis%22">Psoriasis</searchLink><br /><searchLink fieldCode="DE" term="%22ustekinumab%22">ustekinumab</searchLink><br /><searchLink fieldCode="DE" term="%22biologics%22">biologics</searchLink><br /><searchLink fieldCode="DE" term="%22biosimilar%22">biosimilar</searchLink><br /><searchLink fieldCode="DE" term="%22randomized+clinical+trial%22">randomized clinical trial</searchLink><br /><searchLink fieldCode="DE" term="%22Dermatology%22">Dermatology</searchLink><br /><searchLink fieldCode="DE" term="%22RL1-803%22">RL1-803</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Introduction SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.Methods Subjects were randomized to receive 45 mg of SB17 or UST subcutaneously up to Week 40. At Week 28, subjects from the UST treatment group were re-randomized to either switch to SB17 or continue UST. Efficacy, safety, and immunogenicity were assessed up to Week 52.Results Among baseline randomized 503 subjects, 481 subjects were re-randomized at Week 28; continuing SB17 (SB17 + SB17, n = 237), switching from UST to SB17 (UST+SB17, n = 122) or continuing UST (UST+UST, n = 122). The percent change from baseline in Psoriasis Area and Severity Index (PASI) was comparable between treatment groups up to Week 52 (SB17 + SB17: 95.8%, UST+SB17: 95.6%, UST+UST: 94.5% at Week 52). Other efficacy endpoints were also comparable. The incidence of treatment-emergent adverse events (SB17 + SB17: 16.5%, UST+SB17: 13.9%, UST+UST: 23.8%) and the overall incidence of anti-drug antibodies occurring after transition were comparable between treatment groups (SB17 + SB17: 5.6%, UST+SB17: 5.1%, and UST+UST: 6.7%).Conclusion SB17 demonstrated clinical biosimilarity to UST after switching from UST, and maintained long-term comparable efficacy and safety with UST up to Week 52. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 09546634<br />1471-1753<br />0954-6634 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1080/09546634.2024.2436607 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041" linkWindow="_blank">https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.6c23eae0b2e24e7484f961e0f4edf041 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1080/09546634.2024.2436607
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Psoriasis
[Type] => general
)
[1] => Array
(
[SubjectFull] => ustekinumab
[Type] => general
)
[2] => Array
(
[SubjectFull] => biologics
[Type] => general
)
[3] => Array
(
[SubjectFull] => biosimilar
[Type] => general
)
[4] => Array
(
[SubjectFull] => randomized clinical trial
[Type] => general
)
[5] => Array
(
[SubjectFull] => Dermatology
[Type] => general
)
[6] => Array
(
[SubjectFull] => RL1-803
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Steven R. Feldman
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Joanna Narbutt
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giampiero Girolomoni
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jan Brzezicki
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nataliya Reznichenko
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maria Agnieszka Zegadło-Mylik
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Grazyna Pulka
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Magdalena Dmowska-Stecewicz
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Elżbieta Kłujszo
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dmytro Rekalov
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lidia Rajzer
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jiyoon Lee
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Minkyung Lee
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Young Hee Rho
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 12
[Type] => published
[Y] => 2024
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 09546634
)
[1] => Array
(
[Type] => issn-print
[Value] => 14711753
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 35
)
[1] => Array
(
[Type] => issue
[Value] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Journal of Dermatological Treatment
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |